Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study-Reference-Cited by-同舟云学术

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study

Published:2011-03 Issue:9769 Volume:377 Page:914-923
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Cortes Javier,O'Shaughnessy Joyce,Loesch David,Blum Joanne L,Vahdat Linda T,Petrakova Katarina,Chollet Philippe,Manikas Alexey,Diéras Veronique,Delozier Thierry,Vladimirov Vladimir,Cardoso Fatima,Koh Han,Bougnoux Philippe,Dutcus Corina E,Seegobin Seth,Mir Denis,Meneses Nicole,Wanders Jantien,Twelves Chris

Publisher

Elsevier BV

Subject

General Medicine

Reference25 articles.

1. Overview of resistance to systemic therapy in patients with breast cancer;Gonzalez-Angulo;Adv Exp Med Biol,2007

2. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer;Colozza;Oncologist,2007

3. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B;Towle;Cancer Res,2001

4. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth;Jordan;Mol Cancer Ther,2005

5. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389;Kuznetsov;Cancer Res,2004

Cited by 951 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sacituzumab-govitecan in metastatic triple-negative breast cancer: a multicenter effectiveness and safety study;Future Oncology;2024-09-12

2. Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01;Journal of Clinical Oncology;2024-09-12

3. Real-world treatment patterns and outcomes in patients with HR+/HER2− metastatic breast cancer treated with chemotherapy in the United States;ESMO Open;2024-09

4. Current and Novel Treatment Options in Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer;JCO Oncology Practice;2024-08-21

5. Application of Ni/Zr-Mediated Ketone Coupling for the Scalable Synthesis of Homohalichondrin B;Organic Letters;2024-08-19